Q2 2026 saw strong profitability and 10.9% revenue growth, with net revenue surpassing SEK 2 billion and a stable 5.2% adjusted EBIT margin. Growth was driven by both OTC/traded goods and Rx segments, while cash flow was impacted by higher inventory and taxes.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.